A Phase 1/2 Study Of SKI-606 In Philadelphia Chromosome Positive Leukemias
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Dose Limiting Toxicity (DLT)
DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).
Part 1 Baseline up to Day 28
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
3160A4-200
NCT00261846
January 2006
November 2016
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Richmond, Virginia 23249 |
Pfizer Investigational Site | Aurora, Colorado 80012 |
Pfizer Investigational Site | Carmel, Indiana 46032 |
Pfizer Investigational Site | Westminster, Maryland 21157 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Shreveport, Louisiana 71103 |
Pfizer Investigational Site | Washington, District of Columbia 20007-2197 |